Tacrolimus Exposure in Kidney Transplantation

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Mar 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how much of the medication tacrolimus is needed to help prevent kidney transplant rejection in the early months after surgery. Tacrolimus is an important drug that helps keep the body from rejecting the new kidney. The researchers are looking at data from five hospitals in Korea to find the best level of this medication that can keep patients healthy after their transplant.

To be eligible for the study, patients must have received a kidney transplant between January 2005 and December 2014 and be taking tacrolimus as a key medication at two specific times: two months after the transplant for a one-year outcome analysis and twelve months after for a six-year outcome analysis. Participants will be monitored to see how well they are doing with the medication over time. It's important to note that this study is currently recruiting participants, and it excludes patients who had serious complications or other organ transplants during the early months after their kidney transplant.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Renal transplant recipients between January 1, 2005 through December 31, 2014 in one of the five participating centers
• • Patients receiving oral tacrolimus as one of the main immunosuppressant at the start of the defined cohort time (i.e. at post-transplant 2 months for the analysis of 1-year outcomes and at post-transplant 12 months for the analysis of 6-year outcomes)
• Exclusion Criteria:
• • Graft failure occurring within the first 2 month of transplantation
• • Mortality of any cause occurring within the first 2 month of transplantation
• • Patients moving centers during the study period
• • Patients who have received other organ transplantation(s) besides renal transplantation in the defined period